Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies

Journal of Managed Care Medicine

Volumn 15, Issue 2, 2012, Pages 32-39

  Garfield, Susan S ^a   Armstrong, Shannon O ^a  

^a Bridgehead International   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMNIOCENTESIS; ANEUPLOIDY; ARTICLE; CHORION VILLUS SAMPLING; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECHOGRAPHY; HEALTH CARE COST; HIGH RISK PREGNANCY; HUMAN; MATERNAL CARE; NON INVASIVE MEASUREMENT; PRENATAL DIAGNOSIS; PRENATAL SCREENING; REIMBURSEMENT; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SPONTANEOUS ABORTION; TRISOMY;

EID: 84865127702     PISSN: 10941525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free -hCG and pregnancy-associated plasma protein-A. Human Reproduction. 2008; 23(9): 1968-1975.
2. National Library of Medicine. Down syndrome. Available at: http://ghr.nlm.nih.gov/condition/down-syndrome. Accessibility verified January 23, 2012
3. National Institutes of Health. Down Syndrome. Available at: http://www. nichd.nih.gov/publications/pubs/downsyndrome.cfm. Accessibility verified January 23, 2012.
4. National Library of Medicine. Trisomy 18. Available at: http://ghr.nlm.nih.gov/condition/trisomy-18. Accessibility verified January 23, 2012.
5. Savva GM, Walker K, Morris JK. The maternal age-specific live birth prevalence of trisomies 13 and 18 compared to trisomy 21-(Down syndrome). Prenatal Diagnosis. 2010;30: 57-64.
6. National Library of Medicine. Trisomy 13. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002625/. Accessibility verified January 23, 2012.
7. Rasmussen SA, Wong LY C, Yang Q, May KM, Friedman JM. Population-based analyses of mortality in trisomy 13 and trisomy 18. Pediatrics. 2003;111(4): 777-784.
8. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH et al. Firsttrimester or second-trimester screening, or both, for Down's syndrome. New England Journal of Medicine. 2005; 353: 2001-2011.
9. Egan JFX, Kaminsky LM, DeRoche ME, et al. Antenatal Down syndrome screening in the United States in 2001: a survey of maternal-fetal medicine specialists. American Journal of Obstetrics and Gynecology. 2002;187:1230-4
10. Wald NJ, Rodeck C, Hackshaw AK, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technology Assessment. 2003;7:1-77.
11. Mujezinovic F, Alfirevic Z: Procedure-related complications of amniocentesis and chorionic villus sampling. Obstet Gynecol. 2007; 110: 687-694
12. Tabor A, Vestergaard CHF, Lidegaard O. Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet Gynecol. 2009; 34: 19-24
13. Alfirevic Z, Mujezinovic F, Sundberg K, Brigham S. Amniocentesis and chorionic villus sampling for prenatal diagnosis. Cochrane Database System Rev. 2003; 3: CD003252
14. Tabor A, Alfirevic Z. Update on Procedure-related Risks for Prenatal Diagnosis Techniques. Fetal Diagn Ther. 2010; 27:1-7.
15. Driscoll DA, Morgan MA, Schulkin J. Screening for Down syndrome: changing practice of obstetricians. Am J Obstet Gynecol. 2009;200: 459.e1-459.e9
16. Beekhuis JR, de Wolf BTHM, Mantingh A, Heringa MP. The influence of serum screening on the amniocentesis rate in women of advanced maternal age. Prenat Diagn. 1994; 14(3): 199-200.
17. Mueller VM, Huang T, Summers AM, Winsor SHM. The influence of risk estimates obtained from maternal serum screening on amniocentesis rates. Prenat Diagn. 2005; 25(13): 1253-1257.
18. de la Vega A, Verdiales M, Leavitt G. Method of risk assessment affects acceptance rate of amniocentesis. P R Health Sci J. 2002; 21(3):233-5.
19. Jaques AM, Collins VR, Amor DJ, et al. Uptake of prenatal diagnostic testing and the effectiveness of prenatal screening for Down syndrome. Prenat Diagn. 2010; 30(6):522-30
20. Sehnert AJ, Rhees B, Comstock D et al. Optimal Detection of Fetal Chromosomal Abnormalities by Massively Parallel DNA Sequencing of Cell-Free Fetal DNA from Maternal Blood. Clinical Chemistry. 2011, 57:7
21. Bianchi D, Platt L, Goldberg J, et al. Genome wide fetal aneuploidy detection by sequencing of maternal plasma DNA: diagnostic accuracy in a prospective, blinded, multicenter study. AJOG. 2012; 206(1): S367.
22. Verinata Health Inc. MatErnal BLood IS Source to Accurately Diagnose Fetal Aneuploidy (MELISSA). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2011-[cited 2012 Jan 30]. Available from: http://clinicaltrials.gov/ct2/show/NCT01122524 NL M Identifier: NCT01122524.
23. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum a-fetoprotein level. Br J Obstet Gynaecol. 1987; 94:387-402.
24. Cuckle HS, Benn PA. Multi-Marker Maternal Serum Screening for Chromosomal Abnormalities. In: Milunsky A, Milunsky J. Genetic Disorders and the Fetus: Diagnosis, Prevention and Treatment: 6th Edition. Wiley-Blackwell. 2010; 771-804
25. Tul N, Spencer K, Noble P, et al. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn. 1999; 19:1035.
26. Benn PA, Kaminsky LM, et al. Combined Second-Trimester Biochemical and Ultrasound Screening for Down Syndrome. Obstet Gynecol. 2002;100(6): 1168-1176.
27. Nyberg DA, Souter VL, El-Bastawissi A, Young S, Luthhardt F, Luthy DA. Isolated sonographic markers for detection of fetal Down syndrome in the second trimester of pregnancy. J Ultrasound Med. 2001; 20(10):1053-63.
28. Lehman CD, Nyberg D, Winter TC II , Kapur RP, Resta RG, Luthy DA. Trisomy 13 syndrome: Prenatal US findings in a review of 33 cases. Radiology. 1995; 194(1):217-22.
29. Hahnemann JM, Vejerslev LO. Accuracy of cytogenetic findings on chorionic villus sampling (CVS)--diagnostic consequences of CVS mosaicism and non-mosaic discrepancy in centres contributing to EUCROMIC 1986-1992. Prenat Diagn. 1997 Sep;17(9):801-20.
30. Midtrimester amniocentesis for prenatal diagnosis. Safety and accuracy. JAMA. 1976 Sep 27; 236(13): 1471-6.
31. Zoppi MA et al, Nuchal Translucency and the Acceptance of Invasive Prenatal Chromosomal Diagnosis in Women Aged 35 and Older, Obstetrics and Gynecology 2001; 97 (6) 916-920